HOXA13 serves as a biomarker to predict neoadjuvant therapy efficacy in advanced colorectal cancer patients

Neoadjuvant therapy (NAT) for advanced colorectal cancer (ACRC) is a kind of well-evidenced therapy, yet a portion of ACRC patients have poor therapeutic response. To date, no suitable biomarker used for assessing NAT efficacy has been reported. Here, we collect 72 colonoscopy biopsy tissue specimen...

Full description

Saved in:
Bibliographic Details
Published in:Acta biochimica et biophysica Sinica 2023-02, Vol.55 (2), p.304-313
Main Authors: Liu, Shuanghui, Zhang, Rui, Yang, Zhengquan, Wang, Yajiao, Guo, Xingxiu, Zhao, Youjuan, Lin, Huangjue, Xiang, Youqun, Ding, Chunming, Dong, Zhixiong, Xu, Chang
Format: Article
Language:English
Subjects:
Biomarkers
Cell Line, Tumor
Cell Proliferation - genetics
colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
DNA damage response
Gene Expression Regulation, Neoplastic
Homeodomain Proteins - genetics
Homeodomain Proteins - metabolism
HOTTIP
HOXA13
Humans
Neoadjuvant Therapy
RNA, Long Noncoding - genetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neoadjuvant therapy (NAT) for advanced colorectal cancer (ACRC) is a kind of well-evidenced therapy, yet a portion of ACRC patients have poor therapeutic response. To date, no suitable biomarker used for assessing NAT efficacy has been reported. Here, we collect 72 colonoscopy biopsy tissue specimens from ACRC patients before undergoing NAT and investigate the relationship between HOXA13 expression and NAT efficacy. The results show that HOXA13 expression in pretreated tumor specimens is negatively associated with tumor regression (
ISSN:1672-9145
1745-7270
DOI:10.3724/abbs.2022182